Skip to main content
SpringerLink
Log in

Atypical antipsychotic drugs in nonschizophrenic psychiatric disorders

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

This current review looks at the published literature discussing the use of atypical antipsychotics in nonschizophrenic conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Suppes T, Webb A, Paul B, et al.: Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999, 156:1164–1169. One-year randomized open trial of clozapine add-on therapy for treatment resistant patients with a history of mania in a sample of bipolar patients and schizoaffective, bipolar-type patients. It was found that clozapine had significant antimanic and mood-stabilizing properties, but in most patients it had limited anti-depressant efficacy. Clozapine was also effective in nonpsychotic affective illness. The nonpsychotic bipolar patients needed lower doses of clozapine and had greater sensitivity to side effects.

    PubMed  CAS  Google Scholar 

  2. Battegay R, Cotar B, Fleischhauer J, et al.: Results and side effects of treatment with clozapine (Leponex). Compr Psychiatry 1977, 18:423–428.

    Article  PubMed  CAS  Google Scholar 

  3. Zarate CA Jr, Tohen M, Baldessarini RJ: Clozapine in severe mood disorders. J Clin Psychiatry 1995, 56:411–417.

    PubMed  Google Scholar 

  4. Calabrese J, Kimel SE, Woyshville MJ, et al.: Clozapine for treatment-refractory mania. Am J Psychiatry 1996, 153:759–764.

    PubMed  CAS  Google Scholar 

  5. Green AL, Tohen M, Patel JK, et al.: Clozapine in the treatment of refractory psychotic mania. AM J Psychiatry 2000, 157:982–986.

    Article  PubMed  CAS  Google Scholar 

  6. Hillert A, Maier W, Wetzel H, Benkert O: Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome—a functional approach. Pharmacopsychiatry 1992, 25:213–217.

    Article  PubMed  CAS  Google Scholar 

  7. Dwight MM, Keck PE Jr, Stanton SP, et al.: Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 1994, 344:554–555.

    Article  PubMed  CAS  Google Scholar 

  8. Keck PE Jr, Wilson DR, Strakowski SM, et al.: Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995, 56:466–470.

    PubMed  Google Scholar 

  9. Tohen M, Zarate CA Jr, Centorrino F, et al.: Risperidone in the treatment of mania. J Clin Psychiatry 1996, 57:249–253.

    PubMed  CAS  Google Scholar 

  10. Segal J, Berk M, Brook S: Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacology 1998, 21:176–180.

    CAS  Google Scholar 

  11. Vieta E, Gasto C, Colom F, et al.: Treatment of refractory rapid cycling bipolar disorder with risperidone. J Clin Psychopharmacol 1998, 18:172–173.

    Article  PubMed  CAS  Google Scholar 

  12. Müller-Siecheneder F, Müller MJ, Hillert A, et al.: Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998, 18:111–120.

    Article  PubMed  Google Scholar 

  13. Sachs GS and the Rispiridone Study Group: Safety and efficacy of rispiridone vs placebo aas add-on therapy to mood stabilizers in the treatment of manic phase of bipolar disorder.Presented ath the 38th American College of Neuropsychopharmacology. December 1999. Poster #35.

  14. Zarate CA Jr, Narendran R, Tohen M, et al.: Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry 1998, 59:24–28. A retrospective chart review of 150 consecutive patients, factors associated with response to olanzapine were identified. The results showed that patients displaying a moderate to marked response to olanzapine were more likely to be younger, female, receive a diagnosis of bipolar disorder and have a shorter duration of illness, a shorter length of stay prior to olanzapine, and a longer duration of trial.

    PubMed  Google Scholar 

  15. McElroy SL, Frye M, Denicoff K, et al.: Olanzapine in treatmentresistant bipolar disorder. J Affect Disord 1998, 49:119–122.

    Article  PubMed  CAS  Google Scholar 

  16. Tohen M, Todd SM, McElroy SL, et al.: Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999, 156:702–709. A randomized placebo-controlled, double-blind study suggests that olanzapine is effective in the treatment of acute mania, as evidenced by the decreases in total scores on the Young Mania Rating Scale, in severity of mania ratings on the CGI Bipolar version, and in total and positive symptom scores on the Positive and Negative Syndrome Scale. This study showed that the antimanic response to olanzapine, as measured by the Young mania Rating Scale total score, was similar in nonpsychotic and psychotic patients.

    PubMed  CAS  Google Scholar 

  17. Rothschild AJ, Bates KS, Boehringer KL, Syed A: Olanzapine response in psychotic depression. J Clin Psychiatry 1999, 60:116–118. A retrospective study with 30 patients meeting DSM-IV criteria for psychotic depression of unipolar and bipolar type. Fifteen of the patients treated with olanzapine were compared with 15 treated with other antipsychotic agents. Data analyzed showed that olanzapine was safe and effective for patients with psychotic depression.

    Article  PubMed  CAS  Google Scholar 

  18. Zarate CA Jr, Rothschild A, Madrid A, Zapatel J:Clinical predictors of acute response with quetiapine in psychotic mood disorders.J Clin Psychiatry, 2000.

  19. Keck PE Jr, Buffenstein A, Ferguson J, et al.: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998, 140:173–184.

    Article  PubMed  CAS  Google Scholar 

  20. Benedetti F, Sforzini L, Colombo C, et al.: Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998, 59:103–107.

    PubMed  CAS  Google Scholar 

  21. Frankenburg FR, Zanarini MC: Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993, 34:402–405.

    Article  PubMed  CAS  Google Scholar 

  22. Chengappa KNR, Ebeling T, Kang JS, et al.: Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999, 60:477–484.

    Article  PubMed  CAS  Google Scholar 

  23. McDougle CJ, Barr LC, Goodman WK, et al.: Lack of efficacy of clozapine monotherapy in refractory obsessivecompulsive disorder. Am J Psychiatry 1995, 152:1812–1814.

    PubMed  CAS  Google Scholar 

  24. Saxena S, Wang D, Bystritsky A, Baxter LR: Risperidone augmentation of SRI treatment for refractory obsessivecompulsive disorder. J Clin Psychiatry 1996, 57:303–306.

    PubMed  CAS  Google Scholar 

  25. Stein DJ, Bouwer C, Hawkridge S, Emsley RA: Risperidone augmentation of serotonin reuptake inhibitors in obsessivecompulsive and related disorders. J Clin Psychiatry 1997, 58:119–122.

    PubMed  CAS  Google Scholar 

  26. Banov MD, Zarate CA Jr, Tohen M, et al.: Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry. 1994, 55:295–300.

    PubMed  CAS  Google Scholar 

  27. Ghaemi SN, Sachs GS, Baldassano CF, Truman CJ. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Can J Psychiatry 1997, 42:196–199.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Bipolar and Psychotic Disorders Program, Department of Psychiatry, University of Massachusetts Medical School, 361 Plantation Street, 01065, Worcester, MA, USA

    Carlos A. Zarate Jr MD, Meenakshi Vemuri MD, Sarah Cavanagh BS & Michelle Land BS

Authors
  1. Carlos A. Zarate Jr MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meenakshi Vemuri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah Cavanagh BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michelle Land BS
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zarate, C.A., Vemuri, M., Cavanagh, S. et al. Atypical antipsychotic drugs in nonschizophrenic psychiatric disorders. Curr Psychiatry Rep 2, 291–297 (2000). https://doi.org/10.1007/s11920-000-0070-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-000-0070-y

Keywords

Search

Navigation